On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its target price boosted by Barclays from $58.00 to $60.00 in a research ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

Equities research analysts at Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM – Get Free ...

The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based ...

The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ ...

Tandem Diabetes Care reported a strong second quarter in 2024, outperforming expectations in both sales and EBITDA. This impressive performance was largely attributed to the successful launch of the ...